{
    "clinical_study": {
        "@rank": "158160", 
        "arm_group": [
            {
                "arm_group_label": "Standard induction dose", 
                "arm_group_type": "Experimental", 
                "description": "Subjects will be given the standard loading dose of adalimumab at Weeks 0 and 2 followed by the standard maintenance dose beginning at week 4."
            }, 
            {
                "arm_group_label": "Low induction dose", 
                "arm_group_type": "Experimental", 
                "description": "Subjects will be given a low loading dose of adalimumab at Weeks 0 and 2 followed by the standard maintenance dose beginning at week 4."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to investigate the efficacy, safety, and pharmacokinetics in\n      Chinese subjects with Crohn's disease."
        }, 
        "brief_title": "Study to Evaluate the Pharmacokinetics, Safety and Efficacy of Two Treatment Modules in Chinese Subjects With Moderate to Severe Crohn's Disease", 
        "completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Crohn's Disease", 
        "condition_browse": {
            "mesh_term": "Crohn Disease"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Subjects of Chinese decent with full Chinese parentage.\n\n          2. Diagnosis of Crohn's disease (CD) for at least 3 months prior to Week 0 confirmed by\n             endoscopy, radiologic evaluation, and/or histology during the Screening Period.\n\n          3. Crohn's Disease Activity Index (CDAI) \u2265 220 and \u2264 450 despite treatment with oral\n             corticosteroids and/or immunosuppressants.\n\n          4. Subject has a negative Tuberculosis (TB) Screening Assessment.\n\n        Exclusion Criteria:\n\n          1. Subject with ulcerative colitis or indeterminate colitis.\n\n          2. Subject who has had a surgical bowel resection within the past 6 months or who is\n             planning any resection at any time point in the future.\n\n          3. Subject with an ostomy or ileoanal pouch.\n\n          4. Subject who has short bowel syndrome.\n\n          5. Subject with symptomatic known obstructive strictures.\n\n          6. Subject with an internal or external fistula (with the exception of an anal fistula\n             without abscess).\n\n          7. Chronic recurring infections or active TB."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 13, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02015793", 
            "org_study_id": "M14-232"
        }, 
        "intervention": {
            "arm_group_label": [
                "Standard induction dose", 
                "Low induction dose"
            ], 
            "description": "Subjects will be given subcutaneous injections of adalimumab.", 
            "intervention_name": "Adalimumab", 
            "intervention_type": "Biological", 
            "other_name": "Humira\u00ae"
        }, 
        "intervention_browse": {
            "mesh_term": "Adalimumab"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Crohn's Disease", 
            "Pharmacokinetics"
        ], 
        "lastchanged_date": "April 8, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Beijing", 
                        "country": "China", 
                        "zip": "1000700"
                    }, 
                    "name": "Site Reference ID/Investigator# 119755"
                }, 
                "investigator": {
                    "last_name": "Site Reference ID/Investigator# 119755", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Beijing", 
                        "country": "China", 
                        "zip": "100044"
                    }, 
                    "name": "Site Reference ID/Investigator# 118498"
                }, 
                "investigator": {
                    "last_name": "Site Reference ID/Investigator# 118498", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Guangdong", 
                        "country": "China", 
                        "zip": "510080"
                    }, 
                    "name": "Site Reference ID/Investigator# 118496"
                }, 
                "investigator": {
                    "last_name": "Site Reference ID/Investigator# 118496", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Guangzhou, Guangdong", 
                        "country": "China", 
                        "zip": "510655"
                    }, 
                    "name": "Site Reference ID/Investigator# 118497"
                }, 
                "investigator": {
                    "last_name": "Site Reference ID/Investigator# 118497", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Shanghai", 
                        "country": "China", 
                        "zip": "200127"
                    }, 
                    "name": "Site Reference ID/Investigator# 118500"
                }, 
                "investigator": {
                    "last_name": "Site Reference ID/Investigator# 118500", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Shanghai", 
                        "country": "China", 
                        "zip": "200025"
                    }, 
                    "name": "Site Reference ID/Investigator# 118502"
                }, 
                "investigator": {
                    "last_name": "Site Reference ID/Investigator# 118502", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Shanxi Province", 
                        "country": "China", 
                        "zip": "710032"
                    }, 
                    "name": "Site Reference ID/Investigator# 118275"
                }, 
                "investigator": {
                    "last_name": "Site Reference ID/Investigator# 118275", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase 2, Randomized, Double-Blind, Multicenter Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Two Adalimumab Dosing Regimens in Chinese Subjects With Moderately to Severely Active Crohn's Disease and Elevated High-Sensitivity C-reactive Protein", 
        "other_outcome": {
            "description": "AAA concentrations will be measured.", 
            "measure": "Presence of anti-adalimumab antibody (AAA)", 
            "safety_issue": "No", 
            "time_frame": "Up to Week 8"
        }, 
        "overall_contact": {
            "email": "debbie.tokimoto@abbvie.com", 
            "last_name": "Debbie  Tokimoto"
        }, 
        "overall_contact_backup": {
            "email": "tonee.puetz@abbvie.com", 
            "last_name": "Tonee  Puetz"
        }, 
        "overall_official": {
            "affiliation": "AbbVie", 
            "last_name": "Roopal  Thakkar, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Adalimumab serum concentrations will be measured.", 
            "measure": "To characterize the pharmacokinetics of two dosing regimens of adalimumab", 
            "safety_issue": "No", 
            "time_frame": "At Week 8"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02015793"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Hematology, Chemistry, and Urinalysis.", 
                "measure": "Change in Laboratory Test Variables", 
                "safety_issue": "Yes", 
                "time_frame": "From Week 0 to Week 26"
            }, 
            {
                "description": "Blood Pressure, heart rate, respiratory rate, and body temperature.", 
                "measure": "Change in Vital Sign Variables", 
                "safety_issue": "Yes", 
                "time_frame": "From Week 0 to Week 26"
            }, 
            {
                "measure": "Number of subjects with adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 70 days after Week 26"
            }
        ], 
        "source": "AbbVie", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "AbbVie", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}